ASC 10
Alternative Names: ASC-10Latest Information Update: 15 Dec 2024
Price :
$50 *
At a glance
- Originator Ascletis
- Class Antivirals; Small molecules
- Mechanism of Action RNA replicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Respiratory syncytial virus infections
- Phase I COVID 2019 infections; Monkeypox
Most Recent Events
- 30 Oct 2024 Ascletis Pharmaceuticals withdrew phase I clinical trial in COVID-2019 infections in USA (PO) due to business reasons (NCT05596045)
- 11 Jul 2023 Phase-I clinical trials in Monkeypox in China, USA (PO)
- 11 Jul 2023 Phase-II clinical trials in Respiratory syncytial virus infections in USA, China (PO) (Ascletis pipeline, July 2023)